Navigation Links
AstraZeneca and UCL to collaborate to develop regenerative medicines for diabetic retinopathy
Date:9/13/2010

AstraZeneca and UCL (University College London) today announced that they have entered into a collaboration to develop regenerative medicines for diabetic retinopathy (DR).

DR is now the most common cause of vision impairment among those of working age in Western society. The majority of patients with type 1 diabetes will develop retinopathy and about 20-30% will become blind. Moreover, a large number of patients with type 2 diabetes will develop retinopathy as their underlying disease progresses. With the global epidemic of type 2 diabetes, this predicament is set to worsen as over 438 million people are projected to suffer from diabetes and its complications by 2030.

Under the terms of the three-year agreement, AstraZeneca and scientists at the UCL Institute of Ophthalmology will collaborate to identify new therapeutic tools that can modulate the regenerative capacity of stem cells. Dr Marcus Fruttiger, UCL Institute of Ophthalmology, is leading the project and explains that, "These tools could be used either to manufacture transplantable material or to directly stimulate new cell growth in the eye to help restore or improve the vision of those with DR."

"AstraZeneca believes that regenerative medicine offers new opportunities to develop innovative, more effective and safer therapies to benefit patient health. Over the next few years, stem cell technology is likely to contribute to a measurable improvement in our ability to discover and develop candidate drugs, and to target those drugs to the right patient population through a better understanding of the disease process. We are delighted to be combining our drug hunting expertise with the pioneering research ongoing at UCL," said Alan Lamont, Director of Sciences and Technology Alliances at AstraZeneca .

Professor Pete Coffey, UCL Institute of Ophthalmology, adds: "This is a great collaborative opportunity and we're delighted to be working with AstraZeneca to explore the potential of harnessing the regenerative capacity of stem cells to develop a cellular therapy for diabetic retinopathy, which is a major cause of visual impairment and blindness worldwide. AstraZeneca has a proven track record in developing medicines and their involvement in this type of research is very exciting."


'/>"/>

Contact: Dominique Fourniol
d.fourniol@ucl.ac.uk
44-788-183-3274
University College London
Source:Eurekalert

Related medicine news :

1. AstraZeneca Pays $520 Million to Settle Seroquel Whistleblower Claims
2. Freedland Russo Announces $520 Million Settlement Against AstraZeneca
3. Gladstone and Lundbeck collaborate to study neurovascular disease
4. Anakam And Axolotl Collaborate To Deliver A Multi-Factor Authentication Platform For Santa Cruz Health Information Exchange
5. UCLA researchers, US military collaborate to open center for traumatic brain injury
6. Elsevier and InfoDesk collaborate to co-develop federated drug pipeline intelligence solution
7. Carefx to Collaborate with the Cleveland Clinic to Commercialize CCF Business Intelligence Solution
8. Two Hand Therapy Organizations Collaborate on Jam-Packed Educational Weekend
9. BCS Global and Iformata Sign Agreement to Collaborate on the PSVN Initiative to Deliver B2B Video Communications
10. PeopleStreme Collaborates with SkillSoft for Learning Management Content
11. Doctors must collaborate so that patients get full benefit of tamoxifen treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... Colorado (PRWEB) , ... February 11, 2016 , ... Colorado ... Review as one of 334 spine surgeons to know in 2016 . The ... in the field of spine surgery. , Dr. Corenman understands the importance of ...
(Date:2/11/2016)... ... February 11, 2016 , ... The annual list showcases the 20 Most Promising ... team dedication and commitment to the SharePoint ecosystem. A panel of experts and ... goal is to recognize and promote technology entrepreneurship. , The survey was made ...
(Date:2/11/2016)... ... February 11, 2016 , ... Husted Kicking ... San Diego, CA, on February 6th & 7th, 2016 according to kicking coach Michael ... were not invited to the NFL’s combine in Indianapolis,” says Husted. “The NFL uses ...
(Date:2/10/2016)... ... , ... President Obama’s budget proposal yesterday enables the HHS ... via telehealth, estimated to generate more than $160 million in savings over 10 ... Although there is more to be done, this represents an important victory ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... , a full-service health care communications company offering education, research and medical ... for practitioners and specialists working in infectious diseases. , As the all-inclusive ...
Breaking Medicine News(10 mins):
(Date:2/11/2016)... NEW YORK , Feb. 11, 2016 /PRNewswire/ ... a foot-focused suite of products designed to support ... ExoSOLS™, are custom orthotic insoles that combine years ... 1,000 partners in the podiatric field with cutting ... align, and propel . It is supported by ...
(Date:2/10/2016)... DUBLIN , February 11, 2016 /PRNewswire/ ... the addition of the "Molecular Diagnostics ... --> http://www.researchandmarkets.com/research/rp4pg8/molecular ) has announced ... Reports Bundle" report to their offering. ... http://www.researchandmarkets.com/research/rp4pg8/molecular ) has announced the addition of ...
(Date:2/10/2016)... och PITTSBURGH , ... lämnas inte, och detta pressmeddelande får inte ... eller till, och inga anmälningssedlar kommer att ... i, något land där Erbjudandet, distribution av ... Erbjudandet skulle strida mot tillämpliga lagar eller ...
Breaking Medicine Technology: